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Abstract
Bovine Viral Diarrhoea Virus (BVDV) is one of the most serious pathogen, which causes tre-
mendous economic loss to the cattle industry worldwide, meriting the development of
improved subunit vaccines. Structural glycoprotein E2 is reported to be a major immuno-
genic determinant of BVDV virion. We have developed a novel hollow silica vesicles (SV)
based platform to administer BVDV-1 Escherichia coli-expressed optimised E2 (oE2) anti-
gen as a nanovaccine formulation. The SV-140 vesicles (diameter 50 nm, wall thickness
6 nm, perforated by pores of entrance size 16 nm and total pore volume of 0.934 cm3g-1)
have proven to be ideal candidates to load oE2 antigen and generate immune response.
The current study for the first time demonstrates the ability of freeze-dried (FD) as well as
non-FD oE2/SV140 nanovaccine formulation to induce long-term balanced antibody and
cell mediated memory responses for at least 6 months with a shortened dosing regimen of
two doses in small animal model. The in vivo ability of oE2 (100 μg)/SV-140 (500 μg) and
FD oE2 (100 μg)/SV-140 (500 μg) to induce long-term immunity was compared to immuni-
sation with oE2 (100 μg) together with the conventional adjuvant Quil-A from the Quillaja
saponira (10 μg) in mice. The oE2/SV-140 as well as the FD oE2/SV-140 nanovaccine gen-
erated oE2-specific antibody and cell mediated responses for up to six months post the final
second immunisation. Significantly, the cell-mediated responses were consistently high in
mice immunised with oE2/SV-140 (1,500 SFU/million cells) at the six-month time point. His-
topathology studies showed no morphological changes at the site of injection or in the differ-
ent organs harvested from the mice immunised with 500 μg SV-140 nanovaccine compared
to the unimmunised control. The platform has the potential for developing single dose vac-
cines without the requirement of cold chain storage for veterinary and human applications.
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Introduction
Development of veterinary vaccine comes with a spectrum of challenges, as the storage, ship-
ping and administration of the vaccine should be easy and the cost of veterinary vaccine pro-
duction needs to be kept low. [1] Subunit vaccines often need to be refrigerated, require
addition of adjuvants and need to be administered multiple times in order to induce long-term
immunity. Therefore, to reduce the need for booster immunisations, a system needs to be
developed that delivers the antigen and also acts as an efficient adjuvant. Adjuvants are biomol-
ecules that are added to vaccines to stimulate immune responses, however, only a few adjuvants
have been approved for human as well as veterinary use. [2] Another issue that needs to be
taken into account is the transport and storage of subunit vaccines that require cold chain stor-
age, which can be challenging and expensive, especially in remote areas. The storage stability of
the subunit vaccines can be improved by freeze-drying the vaccine formulations. Excipients
such as sugars, surfactants, amino acids and polymers are typically added to the vaccine formu-
lations to prevent degradation in the freeze-drying process and aide in the reconstitution of
vaccines prior to use. [3,4]
Bovine viral diarrhoea virus 1 (BVDV-1) is a single-stranded RNA virus that is a major
contributor to the bovine respiratory disease complex and other disease of cattle. BVDV-1
infection of cattle has been highly investigated in several countries as it causes tremendous eco-
nomic losses to the cattle industry. [5] The major source of new BVDV-1 infection in herds
come from the secretions or body fluids of persistently infected or acutely infected animals. [6]
Immunosuppression caused by BVDV-1 infection can lead to a secondary infection, which is a
major cause of death in BVDV-1 infected cattle. [7] The current BVDV-1 vaccine approved for
use in Australia needs to be refrigerated at 2°C to 8°C.
The structural protein, E2, from BVDV is a major immunogenic determinant and is an
ideal candidate as a subunit vaccine as it can elicit neutralising antibodies. [8] BVDV species
have been classified into type-1 and type-2 viruses, [9,10] and acute infections with BVDV-1
isolates are often subclinical [11], whereas acute infections with BVDV-2 often result in severe
clinical signs with high mortality. [12] In a recent study, a plant expressed truncated version of
BVDV E2 fused to a recombinant single chain antibody (scFv), named APCH was used to tar-
get antigen presenting cells and the APCH-tE2 was found to induce neutralising antibodies in
bovines. [1] Further, BVDV E2 formulated with a combination adjuvant poly[di(sodium car-
boxylatoethylphenoxy)]-phosphazene, a toll-like receptor agonist and an innate defence regu-
lator peptide (designated as TriAdj) induced antibody and cell-mediated immune responses
and provided protection in animals from BVDV-2 infection. [9]
The role of mesoporous silica nanoparticles (MSNs), as antigen carriers and self-adjuvant
vaccines has been investigated to develop successful vaccine delivery systems targeting BVDV-
1. [13,14,15,16] In addition, we have also developed freeze-dried (FD) silica nanoparticle based
vaccine delivery systems and have demonstrated that the model protein ovalbumin (OVA)
adsorbed mesoporous silica nanoparticles can be freeze-dried using 5% (w/v) trehalose and 1%
PEG8000 (w/v) as excipients. [13] The FD 10 μg OVA/150 μg AM-41 formulation was tested
in mice and the nanovaccine stimulated both antibody and cell-mediated immune responses.
[13,16] Amino functionalised hollow mesoporous silica nanoparticles (HMSAs) with small
pore entrance size 2 to 3.5 nm [15] were trialled for adsorption of BVDV codon optimised E2
antigen expressed in E. coli (oE2) (80 mg oE2 bound to per 1 g of HMSA). Although this for-
mulation elicited antibody as well as cell mediated responses after three injections, the con-
straint here was the low antigen binding capacity of the HMSA particles. [15] To address this
issue and in order to move towards our goal of generating enhanced immune response in com-
parison to conventional adjuvant Quil-A, we designed novel silica vesicles (SV) of ~ 50 nm
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with a thin shell wall of 6 nm and controlled entrance size (varying between 5.7 nm to 16 nm).
These SV exhibited higher loading to Ribonuclease A with sustained release behaviour. [17]
The SV-140 with an entrance size of 16 nm significantly improved the oE2 adsorption; ~250
mg oE2 bound to per g SV. The oE2 (50 μg)/SV-140 (250 μg) induced anti-oE2 IgG (105) and
interferon-γ (IFN-γ) responses stronger than the conventional adjuvant Quil-A (anti-oE2 IgG
response of 104) after three subcutaneous injections. [14]
To further develop SVs as vaccine nanocarriers which are self-adjuvanting, the first goal of
the current study was to determine if the oE2/SV140 formulation previously shown to be effec-
tive in generating antibody and cell-mediated response can also stimulate longer term immune
responses with reduced number of injections. The second goal was to develop FD oE2/SV140
formulation and compare it with oE2/SV140 for addressing the issue of storability. In this
work for the first time we have demonstrated that vaccination with oE2 (100 μg)/SV-140
(500 μg) elicited antibody and cell-mediated responses not only after three weeks of two subcu-
taneous injections but also showed strong cell-mediated responses for at least six months after
the second immunisation. In addition, we have also shown that FD oE2/SV-140 nano-formula-
tion also induced both antibody and cell-mediated immune responses. This work for the first
time clearly demonstrates the potential of silica vesicles for developing a nanovaccine with




The SV-140 were prepared and adsorption reactions were set up as previously described. [14]
The oE2 adsorbed SV-140 samples were centrifuged at 16.2 g for 5 min and the supernatants
were removed. Prior to freeze-drying, oE2/SV-140 pellets were resuspended in different combi-
nations and concentrations of excipients (S1 Table). Samples were frozen in liquid nitrogen
then placed in a freeze-dryer (Martin Christ Model LPC-32, Osterode AM Harz, Germany) at
24°C, 0.11 mbar for 22 h for drying. Freeze-dried samples were stored in a vacuum desiccator
at ambient temperature (25°C). The optimal excipients trehalose (5% final concentration) and
glycine (0.1% final concentration) were added to the oE2 bound vesicles and the final volume
adjusted to 1 ml. The oE2 (500 μg) plus Quil-A (2mg/mL) sample was prepared in sterile
injectable water without any excipients and the SV-140 alone with excipients 5% trehalose and
0.1% glycine. All the samples were freeze-dried as described in this section.
Western hybridisation
Following SDS-PAGE electrophoresis the oE2 protein in the nanovaccine formulations was
detected using Western blot hybridisation as previously described [15] using mouse anti-E2
sera at 1:4000 dilution. The secondary antibody anti-mouse Immunoglobulin G HRP conjugate
(Chemicon, Millipore, Billerica, Massachusetts, USA) was used at 1:2,000 dilution and anti-
bovine Immunoglobulin G HRP conjugate (Zymed) at 1:10,000 dilution. Detection was carried
out using an ECL detection kit (GE Healthcare).
Reconstitution and transmission electron microscope (TEM) and
scanning electron microscope (SEM) of lyophilised samples
Samples were reconstituted in 1 mL water. The physical characteristics of the freeze-dried vesi-
cles in solution were observed using transmission electron microscopy (TEM) and scanning
electron microscopy (SEM) before and after reconstitution the freeze-drying preparations.
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Ethics Statement
Mice were euthanised according to the ethics by CO2 inhalation. All procedures were approved
by The University of Queensland, Ethics Committee, (Approval No: 2012001137) as required
by the Animal Care and Protection Act (2001) and The Australian Code for the Care and Use
of Animals for Scientific Purposes (8th Edition). [18]
Immunisation studies conducted in mice
C57BL/6J mice were purchased from and housed in the Biological Resource Facility, The Uni-
versity of Queensland, Brisbane, Australia under specific pathogen-free conditions. Eight week
old female mice were housed in HEPA-filtered cages with eight animals per group in an
environmentally controlled area with a cycle of 12 h of light and 12 h of darkness. Food and
water were given ad libitum.
Pre-immunisation (PI) blood samples were collected prior to the first injection and pro-
cessed as detailed in [14]. The conventional adjuvant Quil-A (Superfos Biosector, Vedback,
Denmark) was resuspended at 2 mg/mL in sterile injectable water (Pfizer, Brooklyn, USA). The
non-FD and FD nanovaccines were prepared by adsorbing oE2 to SV-140 as described above
and in [14], the positive control was oE2 (100 μg) plus Quil-A (10 μg) or FD oE2 (100 μg) plus
Quil-A (10 μg). The negative control was prepared by freeze-drying SV-140 alone with 5% tre-
halose plus 0.1% glycine. The vaccines were administered to investigate the induction of
immune responses and the treatment groups received injections as mentioned in Table 1. Two
injections were administered at 3 week intervals to all the treatment groups except for the
unimmunised group. Dose volumes of 100 μL (in 0.9% saline, Pfizer) were administered by
subcutaneous injection at the tail base using a sterile 27 gauge needle (Terumo, Tokyo, Japan).
Four mice from each group were sacrificed 21 days after the final immunisation. Blood samples
from the remaining four mice were collected every four weeks via tail bleeds for up to six
months and at the end of the trial period animals were sacrificed. The animals were weighed
and monitored for general health once a week. All the animals were assessed weekly and they
remained in good health throughout the duration of the study.
Enzyme-Linked ImmunoSorbent Assay (ELISA) protocol
The detection of oE2-specific antibodies were performed by coating microtitre plates (96 well,
Nunc, Maxisorb, Roskilde, Denmark) with oE2 antigen solution (2 ng/μL, 50 μL) in PBS over-
night at 4°C. The coating solution was removed and the plates were washed once with PBS-T
(1x PBS, 0.1% Tween-20, Sigma-Aldrich) and blocked with Bovine Serum Albumin (5%,
Sigma-Aldrich) and skim milk (5%, Fonterra, Auckland, New Zealand) in 200 μL PBS for 1 h
with gentle shaking at RT. Plates were washed three times with PBS-T.
Table 1. Immunisation groups in mice trial. All doses were administered subcutaneously at the tail
base.
Group Prototype vaccine/Injection Dose
1 oE2 (100 μg) + QuilA (10 μg)
2 FD oE2 (100 μg) + Quil A (10 μg)
3 oE2 (100 μg) / SV-140 (500 μg)
4 FD oE2 (100 μg) / SV-140 (500 μg)
5 FD SV-140 (500 μg)
6 Unimmunised
doi:10.1371/journal.pone.0143507.t001
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Mouse sera samples were diluted from 1:100 to 1:6400 in 50 μL PBS and each dilution was
added to the wells of the blocked plates followed by incubation for 2 h at RT. To detect mouse
antibodies HRP conjugated polyclonal sheep anti-mouse IgG antibodies (Chemicon Australia,
Melbourne, VIC, Australia) diluted in PBS to 1:50,000 were added to each well and incubated
for 1 h at RT with gentle shaking. Plates were washed three times in PBS-T. TMB substrate
(100 μL, Life Technologies) was added to each well and incubated for 15 min at RT; 100 μL of
1N HCl was added to the wells to stop the chromogenic reaction. The plates were read at 450
nm on the BioTek microplate reader (Winooski, US).
Isolation of murine splenocytes and enzyme-linked immunosorbent spot
(ELISPOT) Assay
Spleens were aseptically removed following euthanasia from the four animals sacrificed at
three weeks and the other four at six months after the final immunisation; the collected spleens
were processed as previously described. [14]
Cells from each mouse spleen were seeded at 1.0–1.5 x 105 cells/well in triplicate into Polyvi-
nylidene fluoride (PVDF) ELISPOT plates precoated with monoclonal interferon- γ (IFN-γ)
(Mabtech, Sweden) capture antibody. Cells were incubated in complete DMEMmedium at
37°C and 5% CO2 for 40 h in the presence or absence of 1 μg/mL oE2 antigen or the polyclonal
activator concavalin A (Con A, 1 μg/mL, Sigma Aldrich) as a positive control. IFN-γ ELISPOT
assays were performed according to the manufacturer’s specifications. The ELISPOT plates
were read on an ELISPOT reader (Autoimmun Diagnostika, Strassburg, Germany).
Immunohistochemistry (IHC)
Spleen sections were collected from the sacrificed mice at both the time points three weeks and
six months. A part of the spleen was dissected and frozen in OCT embedding medium and
5 μm sections were cut using Hyrax C60 cryostat. The slides with cryosections were fixed in
cold ethanol on ice for 8 min and then dried at RT for 20 min. The slides were then washed 3 x
5 min in PBS, left to dry at RT for 20 min and using a Dako pen circles were marked around
the sections. The sections were then incubated overnight with the blocking buffer (PBS con-
taining 1% BSA and 5% FBS) at 4°C. Next day, to remove the block the slides were washed for
5 min in PBS three times. The sections were then incubated with Alexa Fluor 488 Goat Anti-
Mouse IgG at 1:500 for 1 h at RT in dark, the slides were then washed as previously described
in PBS. To stain the nuclei of cells the sections were then incubated with DAPI for 5 min and
quickly washed in PBS. The sections were mounted with ProLong1 Gold Antifade mounting
medium and examined under the microscope.
Histopathology
Heart, kidney, liver and injection sites from the sacrificed mice were collected and fixed in 10%
formalin for 48 h. The organs were further processed and embedded in paraffin and 8 μm sec-
tions were cut using the Leica RM 2245 Rotary Microtome. The sections were then stained
using the following haematoxylin and eosin staining procedure. Sections were first Dewaxed in
xylene (3 changes of 2 min each), and then rehydrated in absolute alcohol (2 changes of 2 min
each), in 90% for 2 min, in 70% for 2 min. Then washed in running tap water for 2 min and
stained in haematoxylin for 3 min and again washed in running tap water for 2 min. Sections
were then washed in 70% alcohol for 2 min and stained in eosin for 3 min. Sections were then
washed in 95% alcohol for 2 min, then in absolute alcohol (3 changes of 2 min each). Finally,
the sections were rapidly dehydrated and fixed in xylene (3 changes of 2 min each) and
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mounted in DePeX. The sections were then observed under the Zeiss LSM 510 META confocal
microscope.
Statistical analyses
Statistical analysis of the ELISA data was performed on the average OD values (at 450 nm) of
individual animals in each group (serum dilution of 1:1600). The ELISA results were analysed
by one-way analysis of variance and significant differences between groups were determined
using Tukey’s HSD test (GraphPad Prism for Windows V5.04).
Statistical analysis of the ELISPOT data was performed on the number of SFU/million cells
obtained for individual animals using an unpaired, two-tailed Student’s t-test (Microsoft
Excel).
Results
Physicochemical properties of FD oE2 SV-140
The SV-140 particles investigated in this study have been characterised previously [14,17] and
they have shown to adsorb ~250 mg of oE2 protein to per g of the SV-140 vesicles. [14] Differ-
ent concentrations of 5%, 10% and 20% (w/v) trehalose in combination with 0.1%, 0.5% or 1%
(w/v) glycine as excipients were tested to develop FD oE2/SV-140 nanovaccine following
adsorption. The samples freeze-dried with different concentrations of trehalose and glycine
looked voluminous and snow-like (Fig 1A), as opposed to samples freeze-dried without excipi-
ents, which failed to form a freeze-dried cake (Fig 1B) The FD oE2/SV-140 developed with
combination of 5% trehalose and 0.1% glycine as excipients reconstituted within 10 seconds on
addition of 1 mL of water. However, the samples containing 10% and 20% trehalose required
additional measure like shaking to obtain complete resuspension.
Fig 1. Photograph of FD oE2/SV-140 a) with 5% trehalose and 0.1% glycine; b) without excipients; c) SDS PAGE—adsorption of oE2 on SV-140,
lane 1 –marker, lane 2 –oE2/SV-140 pellet, lane 3 –FD oE2/SV-140 pellet; d) Western hybridisation analysis of oE2 in the vaccine formulations, lane
1 –oE2 protein, lane 2 –oE2 plus Quil-A, lane 3 –oE2/SV-140, lane 4 –FD oE2/SV-140.
doi:10.1371/journal.pone.0143507.g001
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The SDS-PAGE analyses on the reconstituted sample freeze-dried with 5% trehalose and
0.1% glycine showed that the integrity of oE2 protein was preserved post freeze-drying (Fig 1C,
lane 4). Furthermore, Western blot recognised the oE2 protein in the non-FD and the FD vac-
cine formulations (Fig 1D, lane 3 and 4).
The integrity of the vesicles following freeze-drying with 5% trehalose and 0.1% glycine was
further confirmed by TEM and SEM analyses. The TEM results show that the silica vesicles
remained intact and maintained their characteristic round shape and size of ~50 nm post
freeze-drying. The SEM data indicated that the FD SV-140 and FD oE2/SV-140 samples did
not suffer structural collapse (Fig 2C and 2D). The in vivo efficacy of the oE2/SV140 freeze-
dried with 5% trehalose and 0.1% glycine and the oE2/SV-140 was investigated in a mice trial.
Fig 2. Themorphology of FD SV-140 vesicles visualized by transmission electron microscope (TEM), (a) SV-140 and (b) oE2/SV-140 after
lyophilisation in the presence of 5% trehalose and 0.1% glycine. The appearance of FD SV-140 by scanning electron microscope (SEM), (c) SV-140
(d) oE2/SV-140 after lyophilisation in the presence of 5% trehalose and 0.1% glycine.
doi:10.1371/journal.pone.0143507.g002
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Generation of antibody and cell-mediated immune responses three
weeks post immunisation
To evaluate the efficacy of the oE2/SV-140 and FD oE2/SV-140 nanovaccine formulations, ani-
mals were immunised with two subcutaneous vaccinations at a three-week interval. The mice
trial comprised of 48 animals divided into six groups and were immunised as described in
Table 1. PI sera samples were collected prior to immunisation. Three weeks after the second
vaccination sera samples were collected from all eight mice in each group and four randomly
selected mice from each group were sacrificed for the analyses of IFN-γ response. The total IgG
responses of the immunised mice were analysed by anti-oE2-specific ELISA assays. The ani-
mals in all the treatment groups remained healthy and in the normal weight range throughout
the trial period. The non-FD and FD oE2 plus Quil-A and the FD oE2/SV-140 showed a similar
trend of reduction in the level of the antibody responses and were not found to be significantly
different at 1:1600 dilution (Fig 3). The FD oE2/SV-140 induced strong responses (average OD
value of 1.42). Less animal-to-animal variation was observed in the mice treated with the oE2/
SV-140 nanovaccine (average OD value of 1.18) (Fig 3). The average OD values for oE2 plus
Quil-A and FD oE2 plus Quil-A were 2.07 and 1.34 respectively. The mice receiving the FD
SV-140 only and the unimmunised group showed no oE2 specific antibody responses.
ELISPOT assays were used to determine the Th1 cell-mediated IFN-γ responses. Three
weeks post the final immunisation spleens were collected from the four mice of the eight mice
(mice shown as grey in Fig 3). The remaining four mice were retained for investigating the
long-term immune responses. The number of cells producing Spot Forming Units (SFU) indi-
cates cell-mediated immune responses to oE2 antigen. The four individual mice in oE2 plus
Quil-A (551–1500 SFU/million cells) and the FD oE2 plus Quil-A (766–1500 SFU/million
cells) induced strong cell-mediated responses. The oE2 specific memory responses generated
by oE2/SV-140 (599–1500 SFU/million cells; average of four mice 1095 SFU/million cells)
were similar to oE2 plus Quil-A (average of four mice 1094 SFU/million cells). The FD oE2/
SV-140 elicited responses in the range of 222–1500 SFU/million cells; the difference in the Th1
response might be attributed to the mice-to-mice variation with 1–2 mice in each group show-
ing a low response (Fig 4). As expected, the negative controls SV-140 freeze-dried with 5% tre-
halose and 0.1% glycine and unimmunised treatment groups did not generate oE2 specific
responses (Fig 4).
Generation of long-term antibody and cell-mediated immune responses
six months post immunisation
To monitor the long-term responses sera samples were collected once every four weeks for up
to six months after the final second immunisation. oE2-specific humoral immune responses
were measured by ELISA at the different time points. As expected a gradual trend of reduction
in the antibody responses generated by the oE2 injected with conventional adjuvant Quil-A as
well as SV-140 was observed at 7 weeks, 11 weeks, 15 weeks and 19 weeks (S1 Fig). Antibody
responses to the oE2 antigen generated by the oE2 plus Quil-A, FD oE2 plus Quil-A, oE2/SV-
140 as well as FD oE2/SV-140 reduced significantly by the end of six months, however, detect-
able level of antibody responses were still generated at 1:1600 dilution by both oE2/SV-140
(average OD value of 0.19) and FD oE2/SV-140 (average OD value of 0.13, Fig 5) at the six-
month time point. The oE2 plus Quil-A induced strong antibody responses (average OD value
of 0.68), which could be due to the two mice in this group showing higher response. The FD
oE2 plus Quil-A also showed high antibody responses (average OD values of 0.43). The FD
SV-140 alone and the unimmunised treatments did not generate oE2 specific antibody
responses. This is an important finding as for the first time we have demonstrated that the oE2
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adsorbed SV-140 induced long-term antibody responses in mice and also that freeze-drying
the oE2/SV-140 nanovaccine with 5% trehalose and 0.1% glycine maintained the immunologi-
cal integrity of oE2 protein.
Generation of long-term cell-mediated immune response is crucial as it shows uptake of the
antigen by the antigen presenting cells, which is an essential process for developing immunity
to invading pathogens. To determine the long term cell-mediated immune responses spleens
Fig 3. oE2-specific ELISA antibody responses in 8 mice after two subcutaneous immunisations. The individual response for each mouse is shown
using a sera dilution of 1:1600. Group 1 (mouse 1 to 8) received 100 μg oE2 plus 10 μg Quil-A; Group 2 (mouse 1 to 8) received the 100 μg FD oE2 plus
10 μg Quil-A, Group 3 (mouse 1 to 8) received the oE2/SV-140 nanovaccine (100 μg oE2 adsorbed to 500 μg SV-140), Group 4 (mouse 1 to 8) received the
FD oE2/SV-140 nanovaccine (100 μg oE2 adsorbed to 500 μg SV-140), Group 5 (mouse 1 to 8) received the 500 μg FD SV-140 only, Group 6 (mouse 1 to 8)
was the unimmunised group and did not receive any vaccination. The black symbols in each group represent the 4 mice that were monitored for six months.
The letter ‘a’ denotes that the groups were not significantly different. Groups that do not share a common letter were significantly different (* low and
**** high) (p<0.001, unpaired t-test analysis).
doi:10.1371/journal.pone.0143507.g003
Silica Vesicles as Adjuvants and Vaccine Delivery Systems
PLOSONE | DOI:10.1371/journal.pone.0143507 December 2, 2015 9 / 16
were collected from the four sacrificed mice at the end of the trial at six months following the
second immunisation. The negative controls FD SV-140 alone and unimmunised did not gen-
erate oE2 specific cell-mediated responses (Fig 6). The oE2/SV-140 generated very strong long-
term Th1 responses, the average value was found to be significantly higher (1500 SFU/million
cells) than all the treatment groups. The FD oE2/SV-140 treatment group showed some varia-
tion in Th1 cell-mediated immune responses to oE2 antigen as two mice generated low level
responses of 340–1049 SFU/million cells while the other two mice generated high level
responses of 1500 SFU/million cells. Similarly, two mice in the oE2 plus Quil-A group induced
low level of responses (473–690 SFU/million cells) whereas the other two mice generated high
level of responses (1406–1500 SFU/million cells), this varied response can be attributed to
mouse-to-mouse variation. All the four mice in the FD oE2 plus Quil-A group induced low
level responses of 206–583 SFU/million cells.
Immunohistochemistry analyses of mice spleen sections were conducted to determine semi
quantitative IgG responses and the representative results are shown in S2 Fig. The IgG responses
appeared stronger at both the time points (three weeks and six months) with oE2/SV-140
Fig 4. Detection of antigen specific IFN-γ secretion by ELISPOT assay of murine splenocytes from immunised mice. The black bars represent the
number of cells producing IFN-γ in response to the oE2 antigen 3 weeks after the final immunisation. The grey bars show the average for each group and M1
to M4 represent the four individual mice in each group.
doi:10.1371/journal.pone.0143507.g004
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(S2E and S2F Fig) compared to the positive control oE2 plus Quil-A (S2A and S2B Fig). In addi-
tion, the histopathology results demonstrated that administration of the oE2/SV-140, FD oE2/
SV-140 and FD SV-140 alone did not have a detrimental effect on the mouse organs at three
weeks as well as six months as the sections of mice injected with the nanoformulations looked
similar to the unimmunised treatment group (S3A and S3B Fig).
The effectiveness of the non-FD and the FD SV-140 as self-adjuvants and efficient antigen
delivery vehicles were demonstrated by the ELISA and ELISpot assay results which showed
Fig 5. oE2-specific ELISA antibody responses in mice after two subcutaneous immunisations. The individual response for each mouse is shown
using a sera dilution of 1:1600. Group 1 (mouse 5 to 8) received 100 μg oE2 plus 10 μg Quil-A; Group 2 (mouse 5 to 8) received the FD 100 μg oE2 plus
10 μg Quil-A, Group 3 (mouse 5 to 8) received the oE2 nanovaccine (100 μg oE2 adsorbed to 500 μg SV-140), Group 4 (mouse 5 to 8) received the FD oE2
nanovaccine (100 μg oE2 adsorbed to 500 μg SV-140), Group 5 (mouse 5 to 8) received the FD 500 μg SV-140, Group 6 (mouse 5 to 8) was the
unimmunised group and did not receive any vaccination. The letter ‘a’ denotes that the groups were not significantly different. Groups that do not share a
common letter were significantly different (p<0.001, unpaired t-test analysis).
doi:10.1371/journal.pone.0143507.g005
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good oE2-specific antibody and cell-mediated immune responses at three week and six month
time points. This is a significant finding as for the first time we have shown that the SV can
induce long-term humoral and cell-mediated immune responses.
Discussion
For subunit vaccines to be successful commercially it is important that they induce humoral
and cell-mediated responses as well as sustain long-term immunogenicity. This research work
aims on developing a freeze-dried and non freeze-dried veterinary subunit vaccine delivery sys-
tem, using SV-140 as adjuvants and delivery vehicles for BVDV E2 antigen, with the potential
to initiate long-term immunity. Here, for the first time we have shown that the oE2/SV-140
formulation induced humoral and cell-mediated immune responses for up to six months in
mice after two subcutaneous immunisations. In addition, FD of the oE2/SV-140 formulation
also generated long-term antibody and cell-mediated immune responses for up to six months.
Fig 6. Detection of antigen specific IFN-γ secretion by ELISPOT assay of murine splenocytes from immunised mice. The bars represent the number
of cells producing IFN-γ in response to the oE2 antigen six months after the final immunisation. The grey bars show the average for each group and M5 to M8
represent the four individual mice in each group.
doi:10.1371/journal.pone.0143507.g006
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In a recent study, we reported the capacity of SV-140 as nanocarriers for efficient adsorption
of oE2; SV-140 materials displayed excellent cellular uptake proficiency and were found to be
non-toxic on MDBK cells. The oE2/SV-140 formulation was then tested in mice and the ani-
mals were vaccinated with three vaccinations at two week intervals subcutaneously with 50 μg
oE2/250 μg SV-140 and 50 μg oE2 plus 10 μg Quil-A as positive control. The oE2/SV-140
induced higher anti-oE2 IgG as well as IFN-γ responses compared to traditional adjuvant
Quil-A, demonstrating the potential of SV-140 as both efficient vaccine delivery vehicles and
potent adjuvants. [14] These results encouraged us to test the long-term efficacy of the oE2/
SV-140 nanovaccine, as generation of long-term immunity is a requisite for the development
of a successful subunit vaccine. We also developed and tested the ability of the FD oE2/SV-140
nanovaccine to generate immunity in mice to address the issue of cold chain storage of subunit
vaccines.
Freeze-drying is considered an excellent good technique to improve the long-term stability
of the nanoformulations but it is a very complex process. Post freeze-drying the integrity of the
nanoparticles and protein needs to be investigated. Various studies have reported the use of tre-
halose in combination to preserve the immunogenicity of proteins such as lactose dehydroge-
nase, hepatitis B surface antigen (HBsAg) and human serum albumin. [19,20,21] Likewise,
glycine also has been used successfully for freeze-drying of model proteins lactate dehydroge-
nase and glucose 6-phosphate dehydrogenase in a sucrose-glycine based excipient system. [22]
In the past, we have observed that 5% trehalose along with either 1% PEG8000 helped preserve
silica nanoparticles and immunogenicity of OVA protein. [13] For freeze-drying, oE2 adsorbed
SV-140 the combination of 5% trehalose and 0.1% glycine was found to be suitable as it pre-
served the structural integrity of the vesicles as well as the integrity of the oE2 protein. As deter-
mined by western analyses the antigenicity of the FD BVDV oE2 adsorbed on SV-140 was
preserved (Fig 1D lane 4). Sameti et al. demonstrated that the activity of cationic silica nano-
particles was preserved when freeze-dried with either trehalose or glycerol. [23] The freeze-
drying process did not have an adverse affect on the ability of the dried formulations the
oE2/SV-140 and SV-140 to spontaneously go into the solution upon hydration. Furthermore,
as observed by TEM and SEM the structural integrity of the SV-140 adsorbed with oE2 and
SV-140 before and after freeze-drying was well preserved. In addition, previous work from our
laboratory has demonstrated that the FD silica nanovaccine formulations (OVA/AM-41 and
oE2/HMSA) induced both antibody and cell-mediated immune responses in mice [13] and
sheep (personal communication).
In the current study, mice were administered with two vaccinations of the non-FD and the
FD 100 μg oE2/500 μg SV-140 formulations at three week intervals. The animals were main-
tained for up to six months post the final immunisation and mice in all the groups remaining
healthy throughout the trial period. Quantitative toxicity analyses on SV-140 nanovaccine for-
mulations conducted at 0.02 mg/mL and 0.01 mg/mL showed that>85% of the MDBK cells
remained viable. [14] Both oE2/SV-140 and the FD oE2/SV-140 induced oE2 specific antibody
responses (1:1600) at three weeks (average OD range of 1.18 vs. 1.42) and six months (average
OD range of 0.19 vs. 0.13) after the final second immunisation (Figs 3 and 5). As expected,
with time the oE2/SV-140, oE2 plus Quil-A, the FD oE2/SV-140 and FD oE2 plus Quil-A
showed a gradual trend of reduction in the antibody response. Hollow mesoporous silica nano-
particles used to deliver Porcine Circovirus Type 2 ORF2 protein in mice showed significant
reduction in the antibody titres at the six week time point post immunisation. [24] The cell-
mediated response, which is very important part of the anti-viral response, was found to be
strong with oE2/SV-140 and FD oE2/SV-140 at the three week as well as six month time points
(222–1500 SFU/million cells) (Figs 4 and 6). The uniformly strong high cell-mediated response
induced by the four mice (1500 SFU/million cells) in the oE2/SV-140 could be due to the
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sustained release of the antigen from the vesicles. The density and intensity of the signal could
not be directly quantified by the ELISPOT reader. In order to include these animals in the sub-
sequent analyses each was assigned the arbitrary value of 1500 SFU/million cells based on the
upper detection level of the ELISPOT reader. These assigned values were within one standard
deviation of the average values of the ELISPOT controls stimulated with ConA and were there-
fore considered to be realistic estimations. Even though, the oE2 specific cell-mediated immune
responses with the oE2/SV-140 were higher than the FD oE2/SV-140 at 3 weeks as well as six
months, this study confirms the ability of FD oE2/SV-140 to induce long-term humoral and
cell-mediated immune responses. Tonnis et al. [19] demonstrated similar finding as they
found that the freeze-dried aluminum hydroxide adjuvanted HBsAg formulation did not
induce high immune responses but was able to induce both Th1 and Th2 responses. [19]
The elicitation of total IgG response was further confirmed by fluorescent FITC staining of
the spleen sections, which showed that both oE2/SV-140 as well as FD oE2/SV-140 generated
strong antibody responses at three week and six month time points (S2 Fig). Previously, we
have shown that administration of 150 μg AM-41 silica nanoparticles did not cause any mor-
phological changes in the mice organs. [16] Similarly, the histopathology studies on different
organs of mice immunised with the oE2/SV-140, FD oE2/SV-140 and FD SV-140 nanovaccine
treatments groups confirmed that the 50 nm SV are biocompatible materials and that adminis-
tration of 500 μg SV-140 vesicles did not have deleterious side effects (S3 Fig).
In conclusion, the elicitation of humoral and cell-mediated responses by the non-FD and
FD oE2 adsorbed to SV-140 for up to six months after the final second vaccination, further
proves the potential of silica vesicles as a promising new generation adjuvant and delivery vehi-
cle for the development of BVDV subunit vaccine. The efficacy of this adjuvant platform sug-
gests that it can be applied to produce cost effective veterinary subunit vaccines with improved
shelf life.
Supporting Information
S1 Fig. oE2-specific ELISA antibody responses in mice after two subcutaneous immunisa-
tions. The individual response for each mouse is shown using a sera dilution of 1:1600. Group
1 (mouse 5 to 8) received 100 μg oE2 plus 10 μg Quil-A; Group 2 (mouse 5 to 8) received the
FD 100 μg oE2 plus 10 μg Quil-A, Group 3 (mouse 5 to 8) received the oE2 nanovaccine
(100 μg oE2 adsorbed to 500 μg SV-140), Group 4 (mouse 5 to 8) received the FD oE2 nano-
vaccine (100 μg oE2 adsorbed to 500 μg SV-140), Group 5 (mouse 5 to 8) received the FD
500 μg SV-140, Group 6 (mouse 5 to 8) was the unimmunised group and did not receive any
vaccination.
(PDF)
S2 Fig. Representative immunohistochemistry analyses to determine the induction of total
IgG in the spleen sections of the vaccinated animals after three weeks and six months post
the final immunisation, oE2 plus Quil A (a) and (b); FD oE2 plus Quil A (c) and (d); oE2/
SV-140 (e) and (f); FD oE2/SV-140 (g) and (h); FD SV-140 (i) and (j); unimmnised (k) and
(l).
(PDF)
S3 Fig. Histopathology studies of tissue organs from a mouse injected with nanovaccine
immunisations; A) Three weeks post the final immunisation, organs fixed in formalin were
harvested from two mice for each treatment group and embedded in paraffin, sections
were stained with hematoxylin and eosin stain. i) Heart, ii) Injection sites, iii) Kidney, iv)
Liver. B) Six months post the final immunisation, organs fixed in formalin were harvested
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from two mice for each treatment group and embedded in paraffin, sections were stained
with hematoxylin and eosin stain. i) Heart, ii) Injection sites, iii) Kidney, iv) Liver.
(PDF)
S4 Fig. End point titer data of terminal sera bleeds. All the mice were administered 100 μL of
two vaccine doses at 3 week intervals at the tail base. Group 1 (mouse 1 to 8) received 100 μg
oE2 plus 10 μg Quil-A; Group 2 (mouse 1 to 8) received the FD 100 μg oE2 plus 10 μg Quil-A,
Group 3 (mouse 1 to 8) received the oE2 nanovaccine (100 μg oE2 adsorbed to 500 μg SV-
140), Group 4 (mouse 1 to 8) received the FD oE2 nanovaccine (100 μg oE2 adsorbed to 500 μg
SV-140), Group 5 (mouse 1 to 8) received the FD 500 μg SV-140, Group 6 (mouse 1 to 8) was
the unimmunised group and did not receive any vaccination. Sera of individual animals were
diluted from 1:100 to 1:6400.
(PDF)
S5 Fig. Full gel image of Fig 1C and 1D.
(PDF)
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